2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Imaging, Molecular Testing, Cell Expansion, Treatment Considerations, Combination Therapy, Drug Development, Drug-Drug Interactions, Supportive Care, Therapy Sequence, Biological Therapies, Antibody Therapy, Bispecific Antibody Therapy, Chimeric Antigen Receptor, (CAR)-T Cell Therapies, Immunotherapy, Monoclonal Antibody Therapy, Non-Biological Therapies, Chemotherapy, Pharmacology, Adverse Events, Biological Processes, Immune Mechanism, Clinical Practice (Health Services and Quality), Health Economics, Patient Safety, Practice Models, Quality Improvement, Quality of Care, Value, Diseases, Immunology, Immunodeficiency, Infectious Diseases, Viral, Bacterial, Fungal, Other Pathogens, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Plasma Cell Disorders, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Metabolic Disorders, Measurable Residual Disease, ALL, CLL, Non-Hodgkin Lymphoma, B Cell Lymphoma, Indolent Lymphoma, Aggressive Lymphoma, Research, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Health Disparities Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Survivorship, Study Population, Human, Adult, Elderly, Young Adult
PAPER

6276 Determinants of CAR T-cell therapy utilization in relapsed/refractory B-cell lymphomas: A real-world analysis

Xin Ma, BS, Weixi Zhu, PhD2, Rasmi Girijavallabhan Nair, MBBS, MPH, PhD3, Heather Wolfe, MD4, Elif Yilmaz, MD5, Farrukh T Awan, M.D.M.S.,M.B.A.6, Yu-Lun Liu, PhD7, Praveen Ramakrishnan Geethakumari, MD, MS, MBA, FACP8
1 UT Southwestern Medical Center, Dallas, Texas, United States
2 UT Southwestern Medical Center, Dallas, Texas, United States
3 UT Southwestern Medical Center, Dallas, Texas, United States
4 UT Southwestern Medical Center, Dallas, Texas, United States
5 UT Southwestern Medical Center, Dallas, Texas, United States
6 UT Southwestern Medical Center, Dallas, Texas, United States
7 UT Southwestern Medical Center, Dallas, Texas, United States
8 UT Southwestern Medical Center, Dallas, Texas, United States
Background 
Chimeric antigen receptor T-cell (CAR-T) therapy has transformed the treatment landscape for relapsed/refractory (R/R) B-cell lymphomas. However, current CAR-T delivery is resource-intensive, requiring referral to specialized cellular therapy centers, utilizing substantial healthcare infrastructure, thus creating barriers to equitable access beyond clinical eligibility. Although disparities in CAR-T receipt have been described, comprehensive evaluation of patient-, socioeconomic-, and healthcare system-level determinants of CAR-T utilization remain limited. We therefore evaluated factors independently associated with CAR-T utilization among patients with R/R follicular (FL) and diffuse large B-cell lymphomas (DLBCL) using a nationwide electronic health record-derived database. 

Methods 
A retrospective cohort study was conducted using de-identified electronic health record data from Flatiron Health. Adult patients with FL who initiated third-line or later (3L+) systemic therapy and DLBCL who initiated second-line or later (2L+) systemic therapy between January 2011 and May 2024, potentially eligible for standard-of-care CAR-T were included. The primary outcome was receipt of CAR-T. Baseline demographic characteristics, including age, sex, race, ethnicity, insurance status, neighborhood socioeconomic status (SES; 1=lowest, 5=highest), and practice type (academic, community, or hybrid academic/community), were compared between CAR-T recipients and non-recipients. Continuous variables were analyzed using Wilcoxon rank-sum tests and categorical variables using Pearson’s chi-square tests. Separate multivariable logistic regression models were fitted for FL and DLBCL, with all prespecified baseline covariates entered to identify independent predictors of CAR-T receipt. 

Results 
The study population included 787 patients with FL receiving 3L+ therapy, of whom 107 (13.6%) received CAR-T therapy and 680 (86.4%) did not. The DLBCL cohort included 2,381 patients receiving 2L+ therapy, of whom 272 (11.4%) received CAR-T therapy and 2,109 (88.6%) did not. In both cohorts, CAR-T recipients were significantly younger (median age; FL:  61 vs. 70 years; DLBCL: 61 vs. 68 years; both P<0.001), more frequently treated at academic centers and more likely to be from higher-SES category, than non-recipients. Commercial insurance was also more common among CAR-T recipients in univariate analyses. 

On multivariable analysis, advanced age remained independently associated with lower odds of CAR-T receipt in both R/R FL (OR 0.95, 95% CI 0.93–0.97; P<0.001) and DLBCL (OR 0.97, 95% CI 0.96–0.99; P<0.001). Compared with academic centers, treatment at community practices was associated with substantially lower odds of CAR-T utilization in R/R FL (OR 0.29, 95% CI 0.18–0.48; P<0.001) and DLBCL (OR 0.42, 95% CI 0.31–0.56; P<0.001). 

Compared with patients in SES category 1, R/R FL patients from SES categories 2-5 had significantly greater odds of receiving CAR-T (OR range 4.16–4.97; all P<0.05). In R/R DLBCL, patients from SES category 4 were independently associated with increased CAR-T utilization (OR 1.75, 95% CI 1.11–2.84; P=0.020). Race and sex were not independently associated with CAR-T utilization in either cohort. In R/R DLBCL, Hispanic ethnicity was independently associated with increased CAR-T utilization (OR 1.74, 95% CI 1.05–2.82; P=0.027). In R/R FL, Medicare (OR 0.33, 95% CI 0.12–0.80; P=0.022) and other insurance (OR 0.25, 95% CI 0.06–0.80; P=0.035) were associated with lower odds of CAR-T utilization compared with commercial insurance. 

Conclusions 
In this nationwide real-world study, CAR-T utilization was low, at 13.6% among patients with R/R FL and 11.4% among patients with R/R DLBCL. Limitations include retrospective study design, CAR-T eligibility defined per FDA approved treatment-line and unavailability of individual patient clinical assessment. Younger age, treatment at academic centers, and higher socioeconomic status were consistently associated with greater CAR-T utilization whereas older age and care in community practices were independently associated with lower utilization. These findings suggest that healthcare delivery infrastructure and socioeconomic context are major determinants of CAR-T access in routine practice. Future research and health policy efforts should focus on optimizing referral pathways and reducing healthcare barriers to improve equitable access to CAR-T.
Xin Ma, BS: No relevant conflicts of interest to declare.